ClinicalTrials.gg
Not yet recruitingNCT07852247STELLAR IITUpdated Oct 1, 2026

SBRT for Ultra-Central NonSmall Cell Lung Cancer

A Phase 1 interventional study of SBRT in Nonsmall Cell Lung Cancer Stage, sponsored by Georgetown University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Georgetown University · Phase 1, Interventional, and Treatment

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
1,888th of 3,001
35 · median 56
Started
2026
with 133 others
Phase 1
928 of 3,374
134 open now
Primary completion
2031-11
later than 855 of 893 live
Registered
3,355th of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,888th largest by planned enrollment of the 3,001 interventional ones that give a count, is one of 134 that started in 2026, is one of 928 in phase 1, reaches primary completion later than 855 of the 893 other live ones, and was the 3,355th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find out if Five-fraction CyberKnife stereotactic body radiation therapy (SBRT) with real-time Synchrony® motion tracking can treat ultra-central nonsmall cell lung cancer while reducing the amount of serious side effects from SBRT. Participants will

  • receive radiation treatment every other day over two weeks using a machine called the CyberKnife®, which uses a technology called Synchrony® motion management, which tracks your tumor in real time as it moves with your breathing. This allows the radiation beam to follow your tumor during treatment, helping to deliver the radiation more accurately to the tumor while reducing the dose to nearby healthy organs.
  • return for follow up visits after treatment at months 3, 6, 9, 12, 18, 24 and then every year for 5 years to be evaluated
  • complete questionnaires before and after treatment.
03

Conditions studied

  • Nonsmall Cell Lung Cancer Stage

Keywords

  • Ultra-central nonsmall cell lung cancer
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18 or older.
  2. Patients with an (ECOG) performance status of 0-2.
  3. Patients with confirmed tumor location using advanced imaging to ensure accurate classification of ultra-central NSCLC.
  4. Ability to undergo bronchoscopy and Endobronchial ultrasound (EBUS) with adequate fiducial placement
  5. or cytologically confirmed clinical stage T1-T2 N0 M0 NSCLC (AJCC 9th edition), with maximum tumor diameter ≤5 cm.
  6. Absence of overt radiological or bronchoscopy assessed gross endobronchial invasion, invasion of the trachea, esophagus, major blood vessels, or other mediastinal structures.
  7. 4D-CT (computed tomography) scans will be required to evaluate tumor motion and verification at time of simulation:

    ○ Screening for ultra-central tumor deformation between inhalation and exhalation extremities will be performed via 4D-CT to avoid inappropriate margins for significant tumor motion or deformation.

  8. Ultra-central tumors must include:

    o Gross Tumor Volume (GTV) or Planning Target Volume (PTV) located within 1 cm (centimeter) of the Proximal Bronchial Tree (PBT) and/or at least one of the following: (1) GTV or protocol PTV within 1 cm of the PBT; or (2) GTV within 5 mm of or abutting/overlapping the esophagus, heart/pericardium, aorta, pulmonary artery, or pulmonary vein.

  9. Patients are eligible to receive SBRT:

    • Patients deemed suitable for SBRT based on multidisciplinary evaluation;
    • Medically inoperable, decline surgery or high surgical risk as determined by a thoracic surgeon or multidisciplinary tumor board;
    • No prior overlapping thoracic radiation exceeding dose constraints for critical structures;
    • Adequate pulmonary function to tolerate procedure;
    • A minimum of two gold fiducials will be placed in or adjacent to the tumor via bronchoscopy and will be tracked/evaluated by the treating radiation oncologist and/or physicist/dosimetrist to determine quality of fiducial placement for trial inclusion.
  10. Patients are eligible to receive radiation therapy:

    • Candidate for CyberKnife radiosurgery using Synchrony motion management;
    • 4D-CT is required to evaluate tumor motion. Patients with >1.5 cm excursion in any dimension will require a 5 mm PTV margin and remain eligible only if all mandatory Organs-at-risk (OAR) dosimetric and planning constraints can be met; otherwise, they are ineligible for protocol treatment.
    • OAR constraints will be prioritized over target coverage. Patients who cannot meet mandatory airway, esophagus, great vessel, heart, spinal cord, and lung constraints are not eligible for protocol treatment.
  11. Female patients of must have a negative pregnancy test prior to treatment and agree to during and for a defined period after treatment.
  12. Patients who can comply with follow-up visits and treatment plans.
  13. Patients who can provide written prior to study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patients with evidence of nodal involvement (N1-N3) or distant (M1).
  2. Patients with previous radiation therapy to the thorax that would result in overlap with the planned treatment field.
  3. Patients with tumor-associated bronchial compression, defined as visible deformation or narrowing of the trachea, mainstem bronchus, or bronchus intermedius on diagnostic CT, simulation CT, or bronchoscopy.
  4. Patients receiving concurrent chemotherapy, immunotherapy, or targeted therapy during SBRT.
  5. Patients with active connective tissue disease (e.g., lupus, scleroderma, polymyositis, rheumatoid arthritis).
  6. Patients with interstitial lung disease of any etiology.
  7. Patients on Vascular Endothelial Growth Factor (VEGF) inhibitors.
  8. Patients with tumor invasion of any major airways, esophagus, or major blood vessels.
  9. Patients with evidence of endobronchial disease.
  10. Patients who fail to place fiducial markers for Synchrony tracking.
  11. Patients who require alternate fractionation scheduling.
  12. Patients who are pregnant or are breastfeeding.
  13. Patients who are unable to lie flat for the duration of treatment (approximately 45-60 minutes per fraction).
  14. Patients with psychiatric illness or social situation that would limit compliance with study requirements.
  15. Patients who are unable to or unwilling to give .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Cyberknife with Synchrony Motion Tracking

    Radiation: SBRT

Interventions

  • RadiationSBRT

    50 Grays (Gy) delivered in 5 fractions, delivered using Cyberknife with Synchrony motion tracking, every other day over 2 weeks.

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of grade 3 or higher toxicity following SBRT with CyberKnife regimen with real-time motion tracking for ultra-central NSCLC.

    The primary safety endpoint is the cumulative incidence of acute or late grade ≥3 AEs occurring within 12 months and assessed as possibly, probably, or definitely related to protocol treatment. AEs will be graded using the NCI CTCAE version 6.0. Prespecified thoracic AEs include dyspnea, cough, pneumonitis, lung infection, atelectasis, bronchial stenosis or obstruction, bronchopulmonary hemorrhage or hemoptysis, fistula, dysphagia or esophagitis, pleural or pericardial effusion, and chest pain.

    Time frame: Patients will be assessed for toxicity throughout treatment with radiation therapy (RT). Following RT, all participants will be evaluated through 12 months for the primary safety endpoint and will continue protocol safety follow-up through 5 years.

Secondary outcomes

  1. Local control (LC)

    LC will be calculated using the cumulative incidence method and reported along with a 95% exact binomial confidence interval (CI).

    Time frame: Until Trial Completed (up to 5 years)

  2. Regional nodal progression

    The regional nodal progression is defined as the length of time from radiation completion of the first documented presence of enlarged lymph nodes \>1 cm \[short axis\] in the hilum or mediastinum and biopsy confirmed. The Kaplan-Meier method will be used for the analyses, and the median regional nodal progression free time with 95% CI will be reported, respectively, if available.

    Time frame: Until Trial Completed (up to 5 years)

  3. Distant metastasis-free survival (DMFS)

    DMFS is defined as the length of time, from radiation completion to the first evidence of clinical distant metastatic spread of NSCLC outside of the lung cavity or death, whichever occurs first. Patients who are alive and free from clinical distant metastasis will be censored at the date of last follow-up for DMFS. The Kaplan-Meier method will be used for the analyses, and the median DMFS with 95% CI will be reported, respectively, if available.

    Time frame: Until trial completed (up to 5 years)

  4. Progression-free survival (PFS)

    PFS is defined as the length of time, from radiation completion to the first evidence of clinical/radiographic progression, biopsy confirmation when feasible, distant metastasis, or death, whichever comes first. Patients who are alive and free from disease progression will be censored at the date of last follow-up or date of death, whichever occurs first. SOC PET/CT imaging results will be reviewed and collected. The Kaplan-Meier method will be used for the analyses, and the median PFS with 95% CI will be reported, respectively, if available.

    Time frame: From baseline through the follow up period at 3, 6, 9, 12, 18, 24 months followed annually thereafter up to 5 years.

  5. Overall survival (OS)

    OS is defined as the length of time, from radiation completion, a patient lives until death. Patients who are alive will be censored at either the date of last follow-up or date of death, whichever occurs first. The Kaplan-Meier method will be used for the analyses, and the median survival time with 95% CI will be reported, respectively, if available.

    Time frame: Up to 5 years

  6. Incidence of treatment related acute and late grade 2 or higher toxicity and late grade ≥3 toxicity

    The incidence of treatment related acute and late grade ≥2 and late grade ≥3 AEs (AESI) will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 or severity grade when CTCAE grading does not exist. Grade 1 to 5 will be used to characterize the severity of the AE. If CTCAE grading does not exist for an AE, the severity of mild, moderate, severe, life-threatening and death due to the AE, corresponding respectively to Grades 1 - 5, will be used.

    Time frame: From the start of radiation treatment throught 12 months and 24 months.

  7. Patient-Reported Quality of Life Outcomes (QoL)

    Patient-reported QoL outcomes through designated questionnaires. The EORTC QoL questionnaire (QLQ)-C30 is a 30-item form for lung cancer patients that incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea/vomiting), a global health status/ QoL scale, and several single items assessing additional symptoms commonly experienced by cancer patients. The EORTC QLQ-LC13 is a clinically validated tool to assess disease and treatment specific symptoms in lung cancer patients that will participate in clinical trials. Quality of life outcomes will be summarized over time using descriptive statistics and graphical displays. The Wilcoxon signed-rank test will be used for comparisons of QoL between follow-up time points and baseline. Repeated measure models may be employed to assess changes in QoL outcomes over time if deemed necessary.

    Time frame: Pre-radiation/baseline, 3, 6, 9, 12, 18, 24 months post-radiation and then annually thereafter until 5 years.

  8. Pulmonary Function Testing - Forced Expiratory Volume in One Second (FEV1)

    The pulmonary function testing changes will be evaluated including serial PFT, FEV1, FVC (forced vital capacity), DLCO and TLC (total lung capacity) to assess the impact of precision SBRT on respiratory function.

    Time frame: Pre-radiation/baseline to post-radiation follow-up at 6 months, 12 months, 24 months and annually thereafter until 5 years.

  9. Pulmonary Function Testing - FVC (Forced Vital Capacity)

    The pulmonary function testing changes will be evaluated including serial PFT, FEV1, FVC (forced vital capacity), DLCO and TLC (total lung capacity) to assess the impact of precision SBRT on respiratory function.

    Time frame: Pre-radiation/baseline to post-radiation follow-up at 6 months, 12 months, 24 months and annually thereafter until 5 years.

  10. Pulmonary Function Testing - Diffusing Capacity for Carbon Monoxide (DLCO)

    The pulmonary function testing changes will be evaluated including serial PFT, FEV1, FVC (forced vital capacity), DLCO and TLC (total lung capacity) to assess the impact of precision SBRT on respiratory function.

    Time frame: Pre-radiation/baseline to post-radiation follow-up at 6 months, 12 months, 24 months and annually thereafter until 5 years.

  11. Pulmonary Function Testing - TLC (total lung capacity)

    The pulmonary function testing (PFT) changes will be evaluated including serial PFT, FEV1, FVC (forced vital capacity), DLCO and TLC (total lung capacity) to assess the impact of precision SBRT on respiratory function.

    Time frame: Pre-radiation/baseline to post-radiation follow-up at 6 months, 12 months, 24 months and annually thereafter until 5 years.

  12. Correlation of Dose-volume histogram (DVH) parameters for organs-at-risk (OARs) with observed toxicities and local control

    DVH parameters for OARs will be analyzed with their correlation with observed toxicities and local control. Descriptive statistics will be presented for DVH parameters for organs-at-risk (OARs). Two-sided t-test or Mann-Whitney test, ANOVA or Kruskal-Wallis test will be utilized for continuous DHV parameters and Chi-square test or Fisher's exact test will be used for categorical DHV parameters to assess associations between DVH parameters and toxicity and LC, respectively.

    Time frame: through 12 months post-radiation

07

Study locations

1 site
  • Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
    • Nicole Swanson · Contactns1209@georgetown.edu · 202-687-9194
    • Jonathan Lischalk, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2031, 60 months later.

Of 225 non-industry phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's planned 60 months is above that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 1, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2031
CompletionEst.
Nov 2033
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852247
Collaborators
Accuray Incorporated
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2031 (estimated)
Completion
Nov 2033 (estimated)
Last update
Oct 1, 2026

Study contacts

Jonathan Lischalk, MD
Contact
Jonathan.W.Lischalk@gunet.georgetown.edu
2026879194
Jonathan Lischalk, MD
principal investigator · Georgetown University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion